The ACR/ARHP Medication Quick Guides offer easily accessable pharmaceutical information to rheumatologists.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
Information on New Drug Approvals and Medication Safety
Rheumatology-related drug safety, approvals, and what’s in the pipeline.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK
Drug Updates: Apremilast, Belimumab, and More
Information on new approvals and medication safety
Coding Corner Question
Decembers’s Coding Challenge
Watch Those Eyes
What you need to know about Uveitis in Rheumatic Diseases